Phaseline

Companies › ProQR Therapeutics

ProQR Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sepofarsen (QR-110)
CEP290 mRNA positive modulator
CEP290Phase 2Leber Congenital Amaurosis 10–
QR-1123
RNA therapeutic targeting P23H mutation in RHO gene (antisense oligonucleotide or similar
RHOPhase 1Autosomal Dominant Retinitis Pigmentosa–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03913143Sepofarsen (QR-110)Phase 2Leber Congenital Amaurosis 10OphthalmologyJan 2022
NCT04123626QR-1123Phase 1Autosomal Dominant Retinitis PigmentosaOphthalmologyJun 2022

From the company's SEC filings

Cash of 92m EUR on 2025-12-31; operating cash outflow about 53m EUR a year; runway about 21 months at that burn, to Sep 2027

Targets

CEP290 (1) RHO (1)

Companies with the same targets

Ocugen Laboratoires Thea

Companies built like this

Ocugen Opus Genetics Laboratoires Thea Kiora Pharmaceuticals GenSight Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.